BR112018006925A2 - métodos de tratamento de lesões ou patologias associadas com um edema do snc - Google Patents
métodos de tratamento de lesões ou patologias associadas com um edema do sncInfo
- Publication number
- BR112018006925A2 BR112018006925A2 BR112018006925A BR112018006925A BR112018006925A2 BR 112018006925 A2 BR112018006925 A2 BR 112018006925A2 BR 112018006925 A BR112018006925 A BR 112018006925A BR 112018006925 A BR112018006925 A BR 112018006925A BR 112018006925 A2 BR112018006925 A2 BR 112018006925A2
- Authority
- BR
- Brazil
- Prior art keywords
- edema
- snc
- conditions associated
- reducing
- lesions
- Prior art date
Links
- 206010030113 Oedema Diseases 0.000 title abstract 4
- 230000003902 lesion Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000012544 monitoring process Methods 0.000 abstract 2
- 230000000926 neurological effect Effects 0.000 abstract 2
- 206010048962 Brain oedema Diseases 0.000 abstract 1
- 108091006146 Channels Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 208000006752 brain edema Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 229940125400 channel inhibitor Drugs 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238461P | 2015-10-07 | 2015-10-07 | |
| PCT/US2016/055988 WO2017062765A1 (en) | 2015-10-07 | 2016-10-07 | Methods of treating injuries or conditions related to cns edema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018006925A2 true BR112018006925A2 (pt) | 2018-10-16 |
Family
ID=58488580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018006925A BR112018006925A2 (pt) | 2015-10-07 | 2016-10-07 | métodos de tratamento de lesões ou patologias associadas com um edema do snc |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20180280325A1 (https=) |
| EP (1) | EP3359162B1 (https=) |
| JP (4) | JP7349786B2 (https=) |
| KR (2) | KR102681027B1 (https=) |
| CN (2) | CN108348534A (https=) |
| AU (3) | AU2016335767B2 (https=) |
| BR (1) | BR112018006925A2 (https=) |
| CA (1) | CA3001321A1 (https=) |
| EA (1) | EA201890893A1 (https=) |
| ES (1) | ES2940669T3 (https=) |
| HK (1) | HK1257542A1 (https=) |
| IL (1) | IL258509B2 (https=) |
| MA (1) | MA45574A (https=) |
| MX (1) | MX392466B (https=) |
| WO (1) | WO2017062765A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6238969B2 (ja) | 2012-05-08 | 2017-11-29 | エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． | 新規方法 |
| WO2015069956A2 (en) | 2013-11-06 | 2015-05-14 | Aeromics, Llc | Novel formulations |
| CA3001321A1 (en) * | 2015-10-07 | 2017-04-13 | Biogen Chesapeake Llc | Methods of treating injuries or conditions related to cns edema |
| WO2020041905A1 (en) * | 2018-08-31 | 2020-03-05 | The University Of British Columbia | Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds |
| MA55813A (fr) * | 2019-05-02 | 2022-03-09 | Biogen Chesapeake Llc | Procédé de traitement de sujets souffrant de contusions du système nerveux central |
| CN120004770A (zh) * | 2020-07-17 | 2025-05-16 | 上海森辉医药有限公司 | 磺酰脲类衍生物及其医药用途 |
| US12251389B1 (en) * | 2024-04-22 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| WO2025212155A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor |
| US12251388B1 (en) | 2024-05-09 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| WO2025212189A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor |
| WO2025212154A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856360A (en) | 1996-05-03 | 1999-01-05 | Children's Hospital Medical Center | Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock |
| US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| EP2438913B1 (en) | 2002-03-20 | 2020-05-06 | University of Maryland, Baltimore | A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling |
| US20050246000A1 (en) * | 2004-05-03 | 2005-11-03 | Seacoast Technologies, Inc. | Cooled craniectomy |
| WO2009002832A2 (en) | 2007-06-22 | 2008-12-31 | University Of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
| PT2868315T (pt) * | 2007-12-04 | 2017-09-04 | Remedy Pharmaceuticals Inc | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos |
| EP3339190A1 (en) * | 2010-07-19 | 2018-06-27 | Biogen Chesapeake LLC | Containers for glyburide solutions |
| CA3001321A1 (en) * | 2015-10-07 | 2017-04-13 | Biogen Chesapeake Llc | Methods of treating injuries or conditions related to cns edema |
-
2016
- 2016-10-07 CA CA3001321A patent/CA3001321A1/en active Pending
- 2016-10-07 MA MA045574A patent/MA45574A/fr unknown
- 2016-10-07 CN CN201680066630.6A patent/CN108348534A/zh active Pending
- 2016-10-07 KR KR1020187012950A patent/KR102681027B1/ko active Active
- 2016-10-07 EA EA201890893A patent/EA201890893A1/ru unknown
- 2016-10-07 HK HK18116503.6A patent/HK1257542A1/zh unknown
- 2016-10-07 KR KR1020247021781A patent/KR20240105519A/ko not_active Ceased
- 2016-10-07 US US15/763,932 patent/US20180280325A1/en not_active Abandoned
- 2016-10-07 ES ES16854422T patent/ES2940669T3/es active Active
- 2016-10-07 CN CN202211412393.8A patent/CN115737816A/zh active Pending
- 2016-10-07 AU AU2016335767A patent/AU2016335767B2/en active Active
- 2016-10-07 WO PCT/US2016/055988 patent/WO2017062765A1/en not_active Ceased
- 2016-10-07 EP EP16854422.9A patent/EP3359162B1/en active Active
- 2016-10-07 JP JP2018517841A patent/JP7349786B2/ja active Active
- 2016-10-07 BR BR112018006925A patent/BR112018006925A2/pt not_active Application Discontinuation
- 2016-10-07 MX MX2018004286A patent/MX392466B/es unknown
- 2016-10-07 IL IL258509A patent/IL258509B2/en unknown
-
2021
- 2021-02-16 JP JP2021022562A patent/JP2021073317A/ja not_active Withdrawn
- 2021-09-29 US US17/488,591 patent/US11951085B2/en active Active
-
2022
- 2022-11-28 AU AU2022279369A patent/AU2022279369B2/en active Active
-
2023
- 2023-02-13 JP JP2023020327A patent/JP7592768B2/ja active Active
-
2024
- 2024-03-04 US US18/595,205 patent/US20240216309A1/en active Pending
- 2024-08-23 JP JP2024142687A patent/JP7810762B2/ja active Active
- 2024-09-30 US US18/902,504 patent/US20250017880A1/en active Pending
-
2025
- 2025-04-14 AU AU2025202620A patent/AU2025202620A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018006925A2 (pt) | métodos de tratamento de lesões ou patologias associadas com um edema do snc | |
| EP4616902A3 (en) | Nerve stimulation for treating migraine and other headache conditions | |
| EA201500996A1 (ru) | Терапевтические применения эмпаглифлозина | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
| MX2022003193A (es) | Tratamiento de encefalopatia asociada al gen syngap1. | |
| WO2015117032A8 (en) | Treatment systems and methods for affecting glands and other targeted structures | |
| PH12018501313A1 (en) | Augmented acid alpha-glucosidase for the treatment of pompe disease | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| EA201991556A1 (ru) | Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции | |
| MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
| BR112018012255A2 (pt) | método para tratar câncer | |
| BR112017024212A2 (pt) | sequências de uricases melhoradas e métodos de tratamento | |
| EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
| WO2021041539A3 (en) | Pyrido-indole analogues as gpx4 inhibitors | |
| JOP20230157A1 (ar) | طرق مُعالجة فيروس كورونا | |
| MX2017015012A (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
| MX2021008943A (es) | Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos. | |
| GB201202561D0 (en) | Treatment of skin disorders | |
| ZA202104786B (en) | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy | |
| MX2020007619A (es) | Intervenciones dirigidas, encaminadas a reducir los niveles de succinato circulante en un sujeto, y kits y metodo para determinar la eficacia de dichas intervenciones. | |
| BR112018073627A2 (pt) | método para tratar câncer em um paciente | |
| BR112014027646A2 (pt) | método para tratar um indivíduo quanto a um distúrbio proliferativo celular, e método para prevenir ou inibir a perda induzida por uv da atividade de udp-glucuronosiltransferase (ugt) em um indivíduo | |
| MY197563A (en) | Kimchi for preventing or treating helicobacter pylori-associated diseases | |
| DE602006011959D1 (de) | Na+, k+-atpase-expression bei zervixdysplasie und -krebs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |